Background: The aim of the study was to assess the prevalence of antiretroviral drug resistance mutations in HIV-1 from recently diagnosed and untreated patients living in Conakry, Guinea-Conakry and in Niamey, Niger. Methods: The study was performed in two countries of Western Africa -Guinea-Conakry and Niger -using the same survey method in both sites. All newly HIV-1 diagnosed patients, naive of antiretroviral drugs, were consecutively included during September 2009 in each of the two sites. Protease and reverse transcriptase sequencing was performed using the ANRS procedures. Drug resistance mutations were identified according to the 2009 update surveillance drug resistance mutations. Results: In Conakry, 99 patients were included, most of whom (89%) were infected with CRF02_AG recombinant virus. Resistance analysis among the 93 samples showed that ≥1 drug resistance mutation was observed in 8 samples, leading to a prevalence of primary resistance of 8.6% (95% CI 2.91-14.29%). In Niamey, 96 patients were included; a high diversity in HIV-1 subtypes was observed with 47 (51%) patients infected with CRF02_ AG. Resistance analysis performed among the 92 samples with successful genotypic resistance test showed that ≥1 drug resistance mutation was observed in 6 samples, leading to a prevalence of primary resistance of 6.5% (95% CI 1.50-11.50%). Conclusions: We reported the first antiretroviral drug resistance survey studies in antiretroviral-naive patients living in Guinea-Conakry and in Niger. The prevalence of resistance was between 6% and 9% in both sites, which is higher than most of the other countries from Western Africa region.
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, Françoise Brun-Vézinet 1 , Christine Katlama 7, 8 , Vincent Calvez 7, 9, 10 , Anne-Geneviève Marcelin 7, 9, 10 , Bernard Masquelier 2, 7 , Diane Descamps 1, 7 Introduction Mali [3] , Mozambique [4] , Uganda [5, 6] , Rwanda [6] and Zambia [7] showed low prevalence of ARV drug resistance, approximately or below 5%.
In 2009, ARV drugs had been introduced for >5 years in resource-limited settings, and several studies reported a high level of virological failure associated with a high prevalence of drug resistance in HIV-treated patients living in different countries of Africa [8, 9] . In addition, a large proportion of women received ART for the prevention of mother-to-child transmission, mostly represented by a single-dose nevirapine regimen, which is known to be able to rapidly select resistant variants to non-nucleoside reverse transcriptase inhibitors (NNRTIs) [10, 11] . Thus, ARV-resistant variants are likely to circulate in different regions of Africa and there is a need to explore ARV susceptibility of viruses harboured by chronically infected ARV-naive patients.
Little data are available from Guinea-Conakry, where the prevalence of HIV is estimated at 1.6% (approximately 87,000 people) [12] , and in Niger, where the prevalence of HIV is estimated at 0.8% (approximately 60,000 people) [13] . In Guinea-Conakry and Niger, ART first became available in 1999, followed by largescale use of ARV in 2004 with stavudine/lamivudine/ nevirapine recommended for first-line regimen.
The aim of the study was to assess the prevalence of ARV drug resistance mutations in HIV-1 from recently diagnosed and untreated patients living in Conakry, Guinea-Conakry, and in Niamey, Niger.
Methods
The study was performed in two countries of Western Africa, Guinea-Conakry and Niger, using the same survey method in both sites. All newly HIV-1 diagnosed patients attending voluntary counselling testing centres and naive of ARV drugs were consecutively included during the month of September 2009 in each of the two sites: University Hospital of Donka in Conakry, Guinea-Conakry, and University Hospital of Niamey, Niamey, Niger.
Protease and reverse transcriptase (RT) sequencing was performed using the ANRS procedures [14] . Phylogenetic analyses were performed by estimating the relationships among RT sequences and reference sequences of HIV-1 genetic subtypes and circulating recombinant forms (CRF) obtained from the Los Alamos Database [16] . Phylogenetic reconstruction was performed using a Kimura 2-parameter model and the neighbour-joining method. Protease and RT sequences were submitted to GenBank with the following accession numbers: HQ021231-HQ021417.
Plasma concentrations of all ARV drugs were determined using slightly modified UltraPerformance LC ® (UPLC)-MS/MS method (Acquity UPLC-Acquity TQD; Waters Corporation, Milford, MA, USA) as previously described [17] .
Results

Antiretroviral drug resistance among antiretroviralnaive patients from Conakry, Guinea-Conakry
In Conakry, 99 patients were included. The median age of the patients was 39 years (IQR 28-46) and 70 were women. CD4 + T-cell count was available for 76 patients. Median CD4 + T-cell count was 223 cells/ mm 3 (IQR 107-348). Protease and RT sequencing was successful in 93 (94%) samples. Phylogenetic analyses showed that most of the patients, 83 (89%), were infected with CRF02_AG recombinant virus. The subtype distribution of the 10 remaining patients was as follows: 4 (4%) CRF09_cpx, 3 (3%) subtype A, 1 (1%) subtype D, 1 (1%) subtype G, 1 (1%) recombinant CRF40_BF/F. Resistance analysis among the 93 samples showed that ≥1 drug resistance mutation was observed in 8 samples, leading to a prevalence of primary resistance of 8.6% (95% CI 2.91-14.29%; Table 1 ). NRTI resistance mutations were found in 2 samples (2.1%; 95% CI 0.00-5.05%) exhibiting the M184V mutation in one case and a multiresistant virus harbouring 8 mutations (M41L-D67N-T69D-K70R-L74V-V75T-T215F-K219Q) in the second case. NNRTI resistance mutations were carried by 7 samples (7.5%; 95% CI 2.17-12.89%), including 3 viruses exhibiting 2 NNRTI resistance mutations. The most prevalent NNRTI resistance mutation was the K103N mutation detected in four cases. The Y181C, K101E, K103S and G190A mutations were detected in three, two, one and one cases, respectively. Resistance analysis of protease showed the detection of the major PI resistance I84V mutation in 1 case (1%; 95% CI 0.00-3.17%). Overall, 2 patients of this set exhibited dual class-resistant viruses (2.1%; 95% CI 0.00-5.05%).
Antiretroviral drug resistance among antiretroviralnaive patients from Niamey, Niger
In Niamey, 96 patients were included with a median age of 36 years (IQR 30-42), 66 of whom were women.
CD4
+ T-cell count was available for 95 patients. Median CD4 + T-cell count was 291 cells/mm 3 (IQR 189-432). In Niger, a high diversity in HIV-1 subtypes was observed with 47 (51%) patients infected with CRF02_AG, 12 (13%) with subtype G, 11 (12%) with subtype A1 and 10 (11%) with the CRF06_cpx. The remaining patients were infected with CRF36_cpx (n=2), CRF43_02G (n=2), CRF11_cpx (n=1); and seven samples were unclassified HIV-1 subtypes. Resistance analysis performed among the 92 samples with successful genotypic resistance test showed that ≥1 drug resistance mutation was observed in six samples, leading to a prevalence of primary resistance of 6.5% (95% CI 1.50-11.50%; Table 1 ). NRTI resistance mutations were found in 2 samples (2.2%; 95% CI 0.00-5.17%): one showed the Y115F single mutation, and a multiresistant virus harbouring 6 NRTI resistanceassociated mutations (M41L, insertion at codon 69, L74V, M184V, L210W and T215Y) was observed in the remaining case. NNRTI resistance mutations were found in 5 samples (5.4%; 95% CI 0.83-10.03%). The K103N mutation was detected in four cases, and the Y181C in the remaining one. Resistance analysis of protease showed the detection of a major PI resistance mutation, M46L, in one case (1.1%; 95% CI 0.00-3.19%). In this set of patients from Niger, two exhibited dual class-resistant viruses (2.2%; 95% CI 0.00-5.14%).
No clustering of ARV-resistant strains was evidenced by phylogenetic analysis, excepted viruses from patients 84 and 85 at the Guinea-Conakry site (CC et al., data not shown). These patients are partners, which can explain that their plasma virus are clustered and exhibited similar NNRTI resistance mutations ARV drug concentration measurements were performed in samples harbouring drug resistance mutations (n=14) as well as in samples failing to be amplified for sequencing (n=10), showing undetectable ARV plasma concentrations in all cases.
Discussion
Here, we reported a high prevalence in ART-naive patients in Africa with 8.6% and 6.5% of drug resistance mutations observed in recently diagnosed, ARV-naive HIV-infected patients from Guinea-Conakry and from Niger, respectively. These findings show that HIV-1 isolates exhibiting ARV resistance mutations are circulating among treatment-naive patients in both countries.
Furthermore, we can hypothesize that the level of resistance we observed in untreated patients is underestimated because minority resistant variants, undetected by conventional genotyping, were not assessed in our study. Several studies previously showed that their presence should have clinical implications, in particular the presence of NNRTI-resistant variants present in minority proportions might affect virological response to a NNRTI-based regimen [18, 19] .
Some criteria differed between the survey method used in our study and the WHO HIV drug resistance (HIVDR) threshold survey method [20] . First, the median age of the patients in our study was >35 years, 3  42  F  CRF02_AG  --I84V  5  35  F  CRF02_AG  -K103N/S  -27  53  F  CRF02_AG  M184V  K103N, Y181C  -46  21  F  CRF02_AG  M41L, D67N, T69D, K70R,  Y181C, G190A  -L74V, V75T, T215F, whereas HIVDR recommended patients <25 years. In addition, WHO HIVDR criteria recommended ensuring that patients have been infected with HIV within the past 3 years, criteria that we could not include in our study. However, several WHO HIVDR survey method criteria were fulfilled in our study: patients were consecutively included, the number of samples was >47 and there was no known exposure to ARV drugs, including the prevention of mother-to-child transmission in pregnant women. Furthermore, as recommended by the WHO HIVDR survey method criteria, the two selected survey areas of our study are small geographic areas, based in the capital cities where ARV drugs have been widely available for ≥3 years and available to ≥20% of eligible individuals (coverage of 66% in Conakry and 40% in Niamey). In addition, both involved laboratories are part of their respective national system. Such levels of resistance in ARV-naive patients are an important concern for the use of NNRTI in first-line regimen because NNRTI resistance-associated mutations are present in 7.5% and 5.4% of the patients in Guinea-Conakry and Niger, respectively. Furthermore these data argue for considering a more extensive use of PI-containing regimen in first-line. Taken together, these findings emphasize the urgent need of HIV viral load monitoring in resource-limited settings in order to assess the virological outcome of first-line regimen. Our findings reported a threshold level of resistance in untreated patients comprised between 5% and 15% in two different African countries indicating that further surveillance in Conakry, in Niamey, but also in other cities of these countries. Not only does this indicate that further surviellance is warranted in Conakry and Niamey, but also in other cities in these countries to determine the precise level and evolution of HIV-1 primary drug resistance in recently HIV-1-diagnosed patients.
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